share_log

T2 Biosystems | 8-K: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

T2 Biosystems | 8-K: Current report

T2 Biosystems | 8-K：重大事件
美股sec公告 ·  03/28 16:36
Moomoo AI 已提取核心信息
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced on March 28, 2024, the extension of its multi-year capital equipment supplier agreement with Vizient, Inc. through March 31, 2025. The agreement allows Vizient members continued access to T2 Biosystems' products, including the T2Dx Instrument, T2Bacteria Panel, and T2Candida Panel, which are the only FDA-cleared products for direct detection of sepsis-causing pathogens from blood. Vizient, Inc. is the largest member-driven health care performance improvement company in the U.S., representing a significant portion of the nation's health care organizations. The extension of this contract underscores the value of T2 Biosystems' technology in the health care market and its potential to improve patient outcomes by enabling faster targeted therapy for sepsis.
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced on March 28, 2024, the extension of its multi-year capital equipment supplier agreement with Vizient, Inc. through March 31, 2025. The agreement allows Vizient members continued access to T2 Biosystems' products, including the T2Dx Instrument, T2Bacteria Panel, and T2Candida Panel, which are the only FDA-cleared products for direct detection of sepsis-causing pathogens from blood. Vizient, Inc. is the largest member-driven health care performance improvement company in the U.S., representing a significant portion of the nation's health care organizations. The extension of this contract underscores the value of T2 Biosystems' technology in the health care market and its potential to improve patient outcomes by enabling faster targeted therapy for sepsis.
致脓毒症病原体快速检测领域的领导者T2 Biosystems, Inc. 于2024年3月28日宣布，将其与Vizient, Inc.的多年资本设备供应商协议延长至2025年3月31日。该协议允许Vizient成员继续获得T2 Biosystems的产品，包括T2Dx仪器、T2Bacteria Panel和T2Candida试剂盒，这些产品是唯一获得美国食品药品管理局批准的直接检测血液中引起败血症的病原体的产品。Vizient, Inc. 是美国最大的以会员为导向的医疗保健绩效改善公司，占美国医疗保健组织的很大一部分。该合同的延期凸显了T2 Biosystems技术在医疗保健市场中的价值，及其通过实现更快的败血症靶向治疗来改善患者预后的潜力。
致脓毒症病原体快速检测领域的领导者T2 Biosystems, Inc. 于2024年3月28日宣布，将其与Vizient, Inc.的多年资本设备供应商协议延长至2025年3月31日。该协议允许Vizient成员继续获得T2 Biosystems的产品，包括T2Dx仪器、T2Bacteria Panel和T2Candida试剂盒，这些产品是唯一获得美国食品药品管理局批准的直接检测血液中引起败血症的病原体的产品。Vizient, Inc. 是美国最大的以会员为导向的医疗保健绩效改善公司，占美国医疗保健组织的很大一部分。该合同的延期凸显了T2 Biosystems技术在医疗保健市场中的价值，及其通过实现更快的败血症靶向治疗来改善患者预后的潜力。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息